US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
pharma · Advanced Solid Tumors · Non-Hodgkin's Lymphoma
Liposome Company
Taiwan Liposome Company
Liposome Company drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
21 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 21
- Programs
- 6
- Drugs
- 7
- Patents
- 0
Liposome Company pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Liposome Company drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Liposome Company's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Liposome Company in public FDA and regional records.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Liposome Company in public FDA and regional records. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Liposome Company in public FDA and regional records.
-
Development asset linked to Liposome Company in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor